Background: The Clinical and Laboratory Standards Institute recommends reporting minimum inhibitory concentration (MIC) values of vancomycin for . Commercial MIC strips are expensive, and the traditional broth microdilution method is cumbersome. With this background, we attempted to develop and standardize an in-house agar gradient method to determine MIC values of vancomycin for .
Objectives: To develop and validate an in-house vancomycin MIC strip, based on simple agar gradient method for as per bioassay development guidelines.
Materials And Methods: Filter paper gradient strips were made in house and impregnated with varying concentrations of vancomycin to create an antibiotic gradient. During standardization, MICs of ninety clinical strains of and ATCC 29213 were tested by the broth microdilution and commercial strip followed by the in-house strip. During the validation stage, MICs of ninety different clinical strains of and ATCC 29213 were determined by the in-house strip followed by MIC detection by broth microdilution and commercial strips. A reading of more than ± 1log dilution compared with broth microdilution was considered as an outlier.
Results: During the initial stage, there were 7/90 outliers in the clinical strains, and no outliers were seen with the ATCC 29213 control strain. Corrective action included increasing precaution during the antibiotic impregnation on the strip. During validation stage, only 4/90 outliers were observed in the clinical strains. The commercial strips had 29/90 among clinical and 15/30 outliers in the control strain during the prevalidation phase. Despite maintaining cold chain during the validation phase, the outliers for commercial strip were 18/90 and 4/30 for clinical and control strains, respectively.
Conclusion: Reporting vancomycin MIC for may be attempted using the in-house method after validating it with a gold standard broth microdilution method and quality control as per protocol.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771310 | PMC |
http://dx.doi.org/10.4103/JLP.JLP_11_19 | DOI Listing |
Antimicrob Agents Chemother
January 2025
JMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.
Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant (MRSA) and multidrug-resistant (MDR) clinical isolates.
View Article and Find Full Text PDFCureus
December 2024
Department of Microbiology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, IND.
Background: Colistin, a last-resort antibiotic for treating multidrug-resistant Gram-negative bacterial infections, has increased resistance as a result of the emergence of the gene. The 1gene, which confers colistin resistance, is often carried on plasmids, facilitating its spread by horizontal gene transfer among bacterial populations. The rising prevalence of 1mediated resistance poses significant challenges for infection control and treatment efficacy.
View Article and Find Full Text PDFJ Microbiol Immunol Infect
December 2024
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Aeromonas infections pose a significant threat associated with high mortality rates. This study investigates the potential of mitomycin C (MMC), an anticancer drug, as a novel antimicrobial agent against Aeromonas infections.
Methods: We evaluated the minimum inhibitory concentrations (MICs) of MMC and antibiotics against clinical Aeromonas isolates using broth microdilution.
Pak J Pharm Sci
January 2025
Department of Medical Microbiology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Antimicrobial peptides (AMPs) may mitigate the danger of increasing antimicrobial resistance. We aimed to determine the activities of catestatin, temporin A, nisin and cecropin A against Bacteroides fragilis ATCC 25285, Prevotella melaninogenica ATCC 25845, Cutibacterium acnes ATCC 6919, Peptostreptococcus anaerobius ATCC 27337 and Peptostreptococcus stomatis DSM 17678. strains.
View Article and Find Full Text PDFRes Vet Sci
December 2024
Metabolic Modifiers for Aquaculture, Agricultural Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!